Abiopharma

🔍 WEISS MICHAEL S (Director)

Company: TG THERAPEUTICS, INC. (TGTX)

Report Date: 2026-01-08

Detailed Transactions and Holdings:

• Acquired 622,000 shares of Common Stock (Direct)
  Date: 2026-01-08 | Code: A | equity_swap_involved: 0 | shares_owned_after: 9,778,086.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Reflects a grant of restricted shares, all of which will vest on the first anniversary of the date on which the first of any of the following occur: (i) the Company's total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year period; (ii) the Company's TSR exceeds the TSR of the NBI over a 5-year period; (iii) the Company's TSR exceeds the TSR of the NBI over a 7-year period; or (iv) the Company's TSR exceeds the TSR of the NBI over a 9-year period.
• F2: Includes shares of restricted Common Stock, which vest over various time periods.